 Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in heavily pre-treated patient population including cold and HER2-low expressing tumors Dose-dependent immune activation and 4-1BB modulation in both HER2-high and HER2-low expressing patients PRS-344S095012 preclinical data show that the drug candidate induces a dose-dependent anti-tumor response in an anti-PD-L1-resistant mouse model BOSTON, MA ACCESSWIRE April 10, 2021 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today presented a clinical data update from the phase 1 monotherapy study of cinrebafusp alfa PRS-343, a 4-1BBHER2 bispecific for the treatment of HER2-expressing solid tumors, in an oral presentation at the American Association for Cancer Research AACR Virtual Congress 2021. The Company also presented preclinical data for PRS-344S095012, a 4-1BBPD-L1 bispecific the Company is developing with Servier, at a poster session at the congress. 